Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSutro Biopharma

Sutro Biopharma

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
9.62 USD 0.42 ( 4.57%)
Last update at 2026-11-06T21:00:00Z
VOLUME
182655
Market Cap
274.58M

Momentum Score

…

Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
9.21
Low
9.73
High
52 Week Price Range
7.15
Low
43.85
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Sutro Biopharma is a clinical-stage biotechnology company developing protein therapeutics and next-generation antibody–drug conjugates using a cell-free protein synthesis platform that enables site-specific conjugation. Its long-term growth drivers include advancement of clinical-stage candidates, licensing or partnership opportunities for its platform, and increasing demand for targeted oncology treatments, which may benefit from site-specific conjugation approaches.

The company faces material risks from clinical and regulatory setbacks, ongoing capital requirements to fund development, and competitive and manufacturing execution challenges that investors should monitor.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
9.20
Dividend Yield
-
Revenue TTM
45.70M
Revenue Per Share
3.92
Gross Profit TTM
-99.04M
Debt / Equity
-0.12
ROE
-1810.01%
Net Debt
-42.46M
ROCE
-154.99%
Diluted EPS TTM
-17.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -191.18M -225.10M -88.60M -116.70M -105.54M
Net income -191.09M -227.46M -106.79M -119.20M -108.67M
Selling general administrative 41.02M 48.45M 62.58M 59.54M 56.00M
Selling and marketing expenses - - 6.82M - -
Gross profit 95.16M 54.83M 146.91M 67.77M 61.88M
Reconciled depreciation 7.32M 7.22M 6.61M 5.69M 4.84M
Ebit -152.97M -187.67M -74.73M -128.94M -98.52M
Ebitda -145.65M -180.45M -67.92M -125.49M -93.10M
Depreciation and amortization 7.32M 7.22M 6.82M 3.46M 5.42M
Non operating income net other - - - - 0.58M
Operating income -104.95M -238.45M -89.28M -128.94M -98.52M
Other operating expenses 207.44M 300.50M 243.01M 196.72M 160.40M
Interest expense 38.21M 31.07M 23.75M 3.35M 3.14M
Tax provision -0.09M 2.36M 2.38M 2.50M -
Interest income 9.25M 44.42M 12.08M 3.46M 0.58M
Net interest income -32.81M 13.36M -2.25M 0.11M -2.56M
Income tax expense -0.09M 2.36M 18.19M 2.50M 3.14M
Total revenue 102.48M 62.04M 153.73M 67.77M 61.88M
Total operating expenses 200.11M 293.28M 236.19M 196.72M 160.40M
Cost of revenue 7.32M 7.22M 6.82M - -
Total other income expense net -86.23M 13.36M 0.68M 12.24M -7.01M
Net income from continuing ops -191.09M -227.46M -172.45M -119.20M -105.54M
Net income applicable to common shares - - - -119.20M -105.54M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 173.83M 387.21M 470.74M 406.94M 341.41M
Other current assets 5.52M 17.80M 9.85M 11.67M 8.12M
Total liab 306.28M 342.61M 321.09M 189.90M 88.84M
Total stockholder equity -132.45M 44.60M 149.65M 217.05M 252.56M
Other current liab 49.22M 44.14M 53.16M -17.09M 14.50M
Common stock 0.01M 0.08M 0.06M 0.06M 0.05M
Capital stock 0.01M 0.08M 0.06M 0.06M 0.05M
Retained earnings -977.96M -786.87M -559.41M -452.62M -333.41M
Other liab - - - 90.00M 0.15M
Other assets - - - 2.73M 122.89M
Cash 58.13M 190.30M 69.27M 47.25M 30.41M
Total current liabilities 75.13M 131.89M 93.75M 139.47M 41.74M
Current deferred revenue 10.56M 69.78M 20.67M 106.64M 5.50M
Net debt -42.46M -167.15M 113.48M 20.26M 26.96M
Short term debt 7.78M 7.48M 10.48M 17.09M 10.41M
Short long term debt - - 4.06M 12.50M 9.38M
Short long term debt total 15.67M 23.15M 182.75M 67.52M 57.37M
Other stockholder equity 845.48M 831.35M 708.98M 670.22M 586.24M
Property plant equipment - - - 51.06M 51.59M
Total current assets 150.93M 343.31M 421.54M 309.47M 218.51M
Long term investments - - - 32.02M 68.78M
Net tangible assets - - - 217.05M 252.56M
Short term investments 83.30M 126.59M 306.35M 287.11M 167.52M
Net receivables 3.98M 8.62M 36.08M 7.12M 12.45M
Long term debt - - - 3.77M 15.74M
Inventory - - 0.00M -11.67M -
Accounts payable 7.57M 10.47M 9.44M 32.82M 11.33M
Accumulated other comprehensive income 0.02M 0.04M 0.02M -0.62M -0.31M
Common stock total equity - - - - 0.05M
Retained earnings total equity - - - - -333.41M
Non currrent assets other 1.35M 8.03M 4.44M 14.39M 2.53M
Non current assets total 22.90M 43.90M 49.19M 97.48M 122.89M
Capital lease obligations 15.67M 23.15M 29.57M 34.16M 32.26M
Long term debt total - - - - 15.74M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 46.71M 218.51M -18.29M -35.02M -82.00M
Change to liabilities - - - 92.42M -8.77M
Total cashflows from investing activities 45.01M 218.51M -3.92M -35.02M -97.31M
Net borrowings 0.00M -4.08M -12.50M -9.38M -9.38M
Total cash from financing activities 0.04M 94.05M 137.55M 48.31M 3.26M
Change to operating activities - - - 6.64M -1.95M
Net income -191.09M -227.46M -106.79M -119.20M -105.54M
Change in cash -132.17M 121.02M 22.01M 16.84M -175.74M
Begin period cash flow 191.16M 70.14M 48.13M 31.29M 207.02M
End period cash flow 58.99M 191.16M 70.14M 48.13M 31.29M
Total cash from operating activities -177.23M -191.54M -111.62M 3.55M -81.68M
Issuance of capital stock 0.00M 96.53M 27.32M 56.27M 0.00M
Depreciation 7.32M 7.22M 6.82M 5.69M 4.84M
Other cashflows from investing activities - - - 0.01M 0.01M
Change to inventory - - - - -4.54M
Change to account receivables 4.64M 27.46M -28.96M 5.34M -6.89M
Sale purchase of stock - - -0.49M 0.00M -0.01M
Other cashflows from financing activities -0.33M 1.61M 138.08M 1.42M 3.26M
Change to netincome - - - 12.66M 36.63M
Capital expenditures 1.70M 3.10M 4.32M 7.86M 15.32M
Change receivables - - - - -6.89M
Cash flows other operating - - - - -12.52M
Cash and cash equivalents changes - - - - -175.74M
Change in working capital -50.40M 8.90M -34.38M 104.41M -17.62M
Stock based compensation 14.01M 24.69M 24.91M 26.30M 23.24M
Other non cash items 42.92M -4.88M -2.17M -13.65M 6.16M
Free cash flow -178.93M -194.64M -115.93M -4.31M -97.00M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
STRO
Sutro Biopharma		 0.42
4.57%		 9.62 - 10.03 6.01 2.11 2.77 41.71
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Sutro Biopharma

Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

650 881 6500

https://www.sutrobio.com

128

Name Title Year Born
Mr. William J. Newell J.D. CEO & Director 1958
Mr. Edward C. Albini CFO & Sec. 1958
Dr. Trevor J. Hallam Pres of Research & Chief Scientific Officer 1959
Ms. Jane Chung R.Ph. Chief Commercial Officer 1971
Dr. James R. Swartz Ph.D., Sc.D. Founder NA
Dr. Shabbir T. Anik Chief Technical Operations Officer 1953
Ms. Annie J. Chang M.B.A. VP of Investor Relations NA
Mr. David Pauling J.D., M.A. Gen. Counsel NA
Ms. Linda A. Fitzpatrick Chief People & Communications Officer 1957
Dr. Nicki Vasquez Ph.D. Chief Portfolio Strategy & Alliance Officer 1963

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…